Tempus AI, Inc. $TEM Shares Newly Bought by Maxi Investments CY Ltd

Maxi Investments CY Ltd purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM) in the third quarter, Holdings Channel reports. The firm purchased 32,500 shares of the company’s stock, valued at approximately $2,662,000.

A number of other hedge funds also recently added to or reduced their stakes in TEM. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 23.4% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. increased its position in shares of Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after purchasing an additional 821,490 shares in the last quarter. Eagle Health Investments LP acquired a new position in shares of Tempus AI during the first quarter worth $11,588,000. Aristotle Atlantic Partners LLC purchased a new stake in shares of Tempus AI during the 1st quarter valued at $6,179,000. Finally, Fagan Associates Inc. purchased a new stake in shares of Tempus AI during the 3rd quarter valued at $5,265,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Nadja West sold 3,000 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $69.00, for a total value of $207,000.00. Following the transaction, the director directly owned 31,981 shares of the company’s stock, valued at $2,206,689. This represents a 8.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Ryan Bartolucci sold 7,062 shares of the firm’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $529,650.00. Following the completion of the transaction, the chief accounting officer owned 60,804 shares of the company’s stock, valued at $4,560,300. This trade represents a 10.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,030,965 shares of company stock valued at $69,882,564. 24.26% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TEM. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $56.00 to $76.00 in a research report on Tuesday, September 1st. Lake Street Capital lowered Tempus AI to a “hold” rating in a research report on Monday, July 20th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research note on Friday. Rothschild & Co Redburn initiated coverage on Tempus AI in a research note on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price target for the company. Finally, Raymond James Financial set a $80.00 price target on Tempus AI in a research note on Wednesday, September 2nd. Eleven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Tempus AI presently has a consensus rating of “Hold” and a consensus target price of $72.47.

Tempus AI Trading Down 0.7%

Shares of Tempus AI stock opened at $67.16 on Tuesday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $93.38. The firm has a market capitalization of $12.12 billion, a price-to-earnings ratio of -46.64 and a beta of 3.54. The firm’s 50 day simple moving average is $69.29 and its two-hundred day simple moving average is $56.94.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter last year, the company posted ($0.22) earnings per share. The business’s quarterly revenue was up 21.6% on a year-over-year basis. Analysts predict that Tempus AI, Inc. will post -1.43 EPS for the current year.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: EU regulatory certification: Tempus announced that its xR RNA sequencing assay received Class C certification under the European Union’s In Vitro Diagnostic Regulation. The certification covers solid-tumor profiling and supports the company’s ability to market the test for clinical management in Europe, potentially expanding adoption and revenue opportunities. Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
• Positive Sentiment: AI drug-development collaboration: Tempus is participating in a strategic collaboration with Pathos AI and Bristol Myers Squibb focused initially on Alzheimer’s disease and other neurological conditions. The agreement reinforces Tempus’ role in AI-enabled drug development and could create longer-term data and collaboration opportunities, although financial terms were not provided. Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst support: BTIG reaffirmed its “buy” rating and maintained an $80 price target, implying meaningful upside from the stock’s recent level. BTIG Research stock recommendations
• Neutral Sentiment: Earnings setup: Zacks expects Tempus to have favorable conditions for beating estimates in its upcoming report. A beat could support the shares, but the article reflects expectations rather than reported results. Tempus AI expected earnings estimates
• Negative Sentiment: Cash-burn concerns: Continued cash consumption could pressure Tempus’ valuation and increase the need for financing, particularly because the company remains unprofitable and has a high debt-to-equity ratio. What Happens To Tempus AI Stock If Its Cash Burn Continues?
• Neutral Sentiment: Short-interest data: The latest report lists no measurable short interest and a zero-day short-interest ratio, suggesting little evidence of short-covering activity as a current catalyst.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.